Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

BACKGROUND: Recent clinical trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in human lung adenocarcinoma (LUAD) have not achieved satisfactory results. The disappointing results of single-drug treatments have prompted studies about synergistic therapies of CDK4/6i with other drugs. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Yuan, Liao, Cheng-Gong, Zhao, Zheng-Qing, Li, Xiao-Min, Lin, Rong-Jie, Yang, Long, Zhang, He-Long, Kong, Ling-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172583/
https://www.ncbi.nlm.nih.gov/pubmed/35686110
http://dx.doi.org/10.3389/fonc.2022.880153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172583/
https://www.ncbi.nlm.nih.gov/pubmed/35686110
http://dx.doi.org/10.3389/fonc.2022.880153

Ejemplares similares